Sanofi v Amgen antibody case lands front of queue at UPC

The Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UPC announces hearing details for Edwards Lifesciences

31 August 2023 Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString.

Big Pharma

UPC confirms dates for 10x Genomics hearings

22 August 2023 UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.

Big Pharma

UPC: life sciences lead the momentum at new court

15 August 2023 Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.